Literature DB >> 16335080

Pharmaceutical regulation in France 1980-2003.

Valérie Paris1.   

Abstract

This paper provides an overview of French pharmaceutical policy between 1980 and 2003, which was dominated by price control and management of the positive list during the 1980s, with new policy instruments being introduced in the 1990s. The development and diffusion of prescription guidelines has been used to promote more appropriate use of medicines, and some measures aimed at developing the generic market have been implemented. In parallel, attempts have been made to set expenditure caps for physicians' prescriptions and for pharmaceutical companies' turnover. This second option seems to be more durable and effective, although its effectiveness in controlling increases in pharmaceutical expenditure remains limited. Pharmaceutical regulation is now more transparent than it used to be, and the monitoring of prescriptions is steadily improving. However, some areas remain problematic, for example over-prescription of certain classes of medicines such as antibiotics and probably psycholeptics.

Mesh:

Year:  2005        PMID: 16335080     DOI: 10.1002/hpm.817

Source DB:  PubMed          Journal:  Int J Health Plann Manage        ISSN: 0749-6753


  5 in total

Review 1.  The last decade of Italian pharmaceutical policy: instability or consolidation?

Authors:  Giovanni Fattore; Claudio Jommi
Journal:  Pharmacoeconomics       Date:  2008       Impact factor: 4.981

Review 2.  Having your cake and eating it: office of fair trading proposal for funding new drugs to benefit patients and innovative companies.

Authors:  Brian Godman; Alan Haycox; Ulrich Schwabe; Roberta Joppi; Silvio Garattini
Journal:  Pharmacoeconomics       Date:  2008       Impact factor: 4.981

3.  Update of recent reforms in Germany to enhance the quality and efficiency of prescribing of proton pump inhibitors and lipid-lowering drugs.

Authors:  Brian Godman; Ulrich Schwabe; Gisbert Selke; Björn Wettermark
Journal:  Pharmacoeconomics       Date:  2009       Impact factor: 4.981

4.  Crisis and Change: The Making of a French FDA.

Authors:  Constance A Nathanson; Henri Bergeron
Journal:  Milbank Q       Date:  2017-09       Impact factor: 4.911

5.  Why France Spends Less Than the United States on Drugs: A Comparative Study of Drug Pricing and Pricing Regulation.

Authors:  VÉronique C Raimond; William B Feldman; Benjamin N Rome; Aaron S Kesselheim
Journal:  Milbank Q       Date:  2021-03       Impact factor: 6.237

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.